ProfileGDS5678 / 1441953_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 57% 57% 56% 56% 56% 58% 61% 57% 57% 57% 57% 55% 65% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4878657
GSM967853U87-EV human glioblastoma xenograft - Control 23.4500557
GSM967854U87-EV human glioblastoma xenograft - Control 33.4048656
GSM967855U87-EV human glioblastoma xenograft - Control 43.3640656
GSM967856U87-EV human glioblastoma xenograft - Control 53.3888856
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5713658
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7135761
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4358557
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.452757
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4350257
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4450557
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3556355
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9334865
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4471857